Date: 2012-10-18
Type of information: R&D agreement
Compound: M-001 universal influenza vaccine
Company: BiondVax Pharmaceuticals (Israel) MonoSol Rx (USA)
Therapeutic area: Infectious diseases
Type agreement: R&D
Action mechanism:
Disease: influenza
Details: BiondVax Pharmaceuticals will conduct collaborative studies with MonoSol Rx to investigate the activity of BiondVax’s universal influenza vaccine, M-001, when formulated utilizing MonoSol Rx’s PharmaFilm® technology. M-001 in this form would be administered orally and should be stable at room temperature. The multiple advantages of an oral universal influenza vaccine include ease of delivery and increased compliance, due to the absence of needles, as well as ease of distribution. Since the film is small and likely stable at room temperature it could even be mailed in the post. These benefits could prove critical in the unfortunate event of an influenza pandemic, when rapid public access worldwide to influenza vaccines is demanded.
Financial terms:
Latest news:
